CanSino Biologics Inc. (stock code: 06185) published the Monthly Return for the period ended 31 January 2026. The total authorized share capital remained at RMB247,043,801, encompassing 132,670,900 H shares listed on The Stock Exchange of Hong Kong Limited and 114,372,901 A shares listed on the STAR Market of the Shanghai Stock Exchange. There was no reported change in the number of authorized shares during the month.

The number of issued H shares and A shares remained constant throughout January 2026, at 132,670,900 and 114,372,901 respectively, with no treasury shares reported. The company confirmed compliance with the applicable public float requirements for its H shares.

In January 2026, there were no increases in issued shares from the 2025 Core Management H Share Option Scheme. A total of 860,000 options remained outstanding, with no new shares issued or treasury shares transferred. Meanwhile, under the 2025 Restricted A Share Incentive Scheme, no additional shares were issued during the month, leaving 2,054,600 restricted shares available for future issuance.